Melanoma News and Research

Latest Melanoma News and Research

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.

10 Jun 2011

Eliminating ABCB5-expressing cells crucial for successful colorectal cancer treatment

Researchers at Children's Hospital Boston have found a marker called ABCB5 that both tags a small proportion of cells within colorectal cancers and fuels resistance in those cells to standard treatments. The results indicate that eliminating ABCB5-expressing cells is crucial for successful colorectal cancer treatment, while adding to the growing body of evidence for a theory of cancer growth called the cancer stem cell hypothesis.

9 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

IsoRay completes Iotrex license agreement with Dr. Reddy's

IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.

7 Jun 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.

7 Jun 2011

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

DxTerity Diagnostics announced today that it has acquired intellectual property rights to several blood based cancer diagnostic tests from SourceMDx Inc.

7 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Independent investigators reported today full results from the NEO3-09 study, reaffirming earlier top-line results that showed Lymphoseek met all primary and secondary endpoints and exhibited superior performance to vital blue dye in intraoperative lymphatic mapping (ILM) procedures.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Study finds consistent link between Parkinson's disease and melanoma

An analysis of several studies shows that people with Parkinson's disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases.

7 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Scientists discover key molecule that targets tumour blood vessels

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

7 Jun 2011

Senescent melanoma cells express an inflammatory secretome

Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In this paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.

6 Jun 2011

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced an expanded clinical focus to include an autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.

6 Jun 2011

Majority of Canadian parents concerned about sun protection for children, CDA survey

Almost all Canadian parents (92%) are concerned about sun protection for their children, a new survey for the Canadian Dermatology Association (CDA) shows.

6 Jun 2011

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Melanoma News and Research

Latest Melanoma News and Research

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Eliminating ABCB5-expressing cells crucial for successful colorectal cancer treatment

NYU Cancer Institute scientists present new research findings at ASCO 2011

IsoRay completes Iotrex license agreement with Dr. Reddy's

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Study finds consistent link between Parkinson's disease and melanoma

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Scientists discover key molecule that targets tumour blood vessels

Senescent melanoma cells express an inflammatory secretome

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Majority of Canadian parents concerned about sun protection for children, CDA survey

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in